7/4/2023 0 Comments Narcolepsy cataplexy![]() Although these neurological manifestations of COVID-19 suggest a possibly acute or subacute neuropathogenicity of the virus, the risk of long-term neurological sequelae in patients affected by SARS-CoV2 is not understood and currently debated. The occurrence of neurological manifestations, including encephalitis, stroke, headache, seizures, Guillain–Barrè syndrome, is increasingly reported in patients with COVID-19. SARS-CoV2 infection is responsible for a heterogeneous clinical syndrome, leading to severe pneumonia and acute respiratory distress syndrome (ARDS), titled coronavirus disease 2019 (COVID-19). In December 2019, a novel coronavirus, named severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2), emerged from China and spread worldwide as pandemic. In this short narrative review, we summarize the clinical evidence supporting the rationale for investigating SARS-CoV2 infection as risk factor for these neurological disorders, and suggest the opportunity to perform in the future SARS-CoV2 serology when diagnosing these disorders. Specifically, Parkinson’s disease, multiple sclerosis and narcolepsy present several pathogenic mechanisms that can be hypothetically initiated by SARS-CoV2 infection in susceptible individuals. Moreover, SARS-CoV2 immunopathology and tissue colonization in the gut and the central nervous system, and the systemic inflammatory response during COVID-19 may potentially trigger chronic autoimmune and neurodegenerative disorders. Occurrence of acute and subacute neurological manifestations (encephalitis, stroke, headache, seizures, Guillain–Barrè syndrome) is increasingly reported in patients with COVID-19. SARS-CoV2 infection is responsible for a complex clinical syndrome, named Coronavirus Disease 2019 (COVID-19), whose main consequences are severe pneumonia and acute respiratory distress syndrome.
0 Comments
Leave a Reply. |